Sanctuary Advisors LLC Boosts Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Sanctuary Advisors LLC raised its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 21.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,120 shares of the company’s stock after acquiring an additional 721 shares during the period. Sanctuary Advisors LLC’s holdings in Medpace were worth $1,392,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Signaturefd LLC grew its stake in Medpace by 4.9% during the 2nd quarter. Signaturefd LLC now owns 559 shares of the company’s stock worth $230,000 after buying an additional 26 shares during the last quarter. Wealth Alliance grew its stake in shares of Medpace by 2.9% during the second quarter. Wealth Alliance now owns 970 shares of the company’s stock worth $399,000 after acquiring an additional 27 shares during the last quarter. Centaurus Financial Inc. increased its holdings in shares of Medpace by 2.0% during the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock valued at $505,000 after acquiring an additional 29 shares in the last quarter. Commonwealth Equity Services LLC raised its position in shares of Medpace by 0.7% in the 2nd quarter. Commonwealth Equity Services LLC now owns 4,340 shares of the company’s stock valued at $1,787,000 after purchasing an additional 32 shares during the last quarter. Finally, Lindenwold Advisors INC boosted its stake in Medpace by 1.6% in the 3rd quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock worth $676,000 after purchasing an additional 32 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Trading Up 0.6 %

Shares of MEDP stock opened at $337.28 on Friday. Medpace Holdings, Inc. has a twelve month low of $277.72 and a twelve month high of $459.77. The stock has a 50 day moving average of $339.14 and a 200 day moving average of $366.30. The stock has a market cap of $10.48 billion, a P/E ratio of 29.53, a P/E/G ratio of 1.89 and a beta of 1.37.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The firm had revenue of $533.32 million during the quarter, compared to analysts’ expectations of $540.99 million. During the same period in the previous year, the business posted $2.22 EPS. The business’s revenue was up 8.3% compared to the same quarter last year. On average, research analysts predict that Medpace Holdings, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Ratings Changes

MEDP has been the topic of a number of recent analyst reports. Truist Financial cut their price target on shares of Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. William Blair reissued an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Baird R W cut Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. UBS Group lowered Medpace from a “buy” rating to a “neutral” rating and cut their price objective for the company from $420.00 to $350.00 in a report on Friday, September 27th. Finally, TD Cowen decreased their target price on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $380.56.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.